A protein-dissolving enzyme whose most consistent support is easing swelling and jaw stiffness after dental surgery, with weaker signals for injury swelling, mucus clearance, and general pain. Claims about thinning blood, dissolving arterial deposits, and slowing aging-related inflammation rest mainly on laboratory work. Well tolerated short-term, though blood thinners and surgery raise a real bleeding concern; long-term safety is untested. (Full Review)

Protocol

Dose

10–60 mg/day

20,000–120,000 units; start low, titrate over 1–2 weeks

Frequency

2–3× daily

Split dosing given the short half-life

Timing

Empty stomach

Enteric-coated; 30 min before or 2 h after food

Time to effect

Dental swelling

Several days–2 weeks

Best-supported use

Injury swelling

3–10 days

Acute soft-tissue sprain

Chronic use

No reliable timeframe

Gradual and unproven

Benefits

Medium: Reduced swelling and jaw stiffness after dental surgery

Low: Reduced swelling after soft-tissue injury; improved mucus clearance in airway and sinus conditions; general pain and inflammation relief

Speculative: Fibrinolytic and cardiovascular plaque-dissolving effects; anti-biofilm and antimicrobial-adjunct effects; lowering chronic low-grade inflammation

Contraindications

Bleeding or clotting disorders

Anticoagulant or antiplatelet medication use

Within ~2 weeks before or after surgery

Active untreated infection

Pregnancy or breastfeeding

Known hypersensitivity to the enzyme

Key Interactions

Aspirin and other NSAIDs (ibuprofen, naproxen)

Blood-thinning supplements (nattokinase, lumbrokinase, bromelain, fish oil, garlic, Ginkgo biloba, vitamin E, high-dose curcumin)

Antibiotics (physician-directed)

Risk & Side Effects

Medium: Increased bleeding and bruising risk

Low: Gastrointestinal discomfort; skin and allergic reactions

Speculative: Lung reactions; facilitation of infection spread

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks body-wide inflammation, the main target
ESR	< 15 mm/hr	Secondary, slower marker of inflammation
Platelet count	150–400 × 10⁹/L	Screens bleeding safety
PT/INR	~0.9–1.1 (if not on anticoagulants)	Assesses baseline clotting time
Fibrinogen	200–400 mg/dL	Reflects clotting capacity and inflammation

Cadence: Baseline before starting, at 4–8 weeks, then every 6–12 months

Qualitative Assessment

Swelling, bruising, or joint/tissue puffiness at the area of concern
Pain levels and mobility (jaw opening after dental work, ankle function after a sprain)
Sinus or airway congestion and ease of clearing mucus
Any new bruising, bleeding, rash, or breathing changes (safety signals)
General energy and sense of well-being

Serrapeptase for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment